PMGC Holdings Inc.
PMGC Holdings Inc. is a U.S.-based diversified holding company that owns and operates a portfolio of subsidiaries across biotechnology, scientific research, and specialized manufacturing. Its structure combines direct operating businesses with investment and acquisition activities through PMGC Capital LLC and other wholly owned subsidiaries.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueDirect investments, strategic lending, and acquisition of undervalued assets and businesses.
Development of aesthetic medicines and therapeutic products through NorthStrive BioSciences.
Medical research activities and collaboration with Canadian universities through PMGC Research.
CNC machining and high-tolerance component production through AGA Precision Systems.
IT packaging and related services provided by operating subsidiaries such as Pacific Sun Packaging.
Customers
PMGC sells to a mix of business customers, research partners, and capital counterparties rather than a single end market. Its operating subsidiaries serve industrial and technology buyers, while its biosciences and research activities are aimed at commercial partners, universities, and future healthcare customers. The capital allocation platform targets undervalued businesses and assets that can be acquired, financed, or developed into standalone operating companies.
Buy CNC-machined and high-tolerance components for production and engineering applications.
Buy packaging-related services from operating subsidiaries for product handling and shipment needs.
Collaborate on scientific research and development, often supported by grants and partnerships.
Support development, validation, and future licensing of biosciences assets and technologies.
Provide or receive capital through investments, lending, acquisitions, and structured transactions.
Strategy
PMGC’s strategy is to build value through acquisitions, subsidiary formation, and commercialization of newly acquired or licensed assets. It is also pursuing clinical validation and development for biosciences assets while expanding operating businesses that can generate revenue and EBITDA. The portfolio approach is intended to combine operating cash flow, scientific development, and capital allocation into a broader holding-company platform.
The holding-company model depends on buying assets below intrinsic value and improving them through capital allocation.
Clinical validation and IND progress are needed to create licensing, partnership, or commercialization value.
Operating businesses diversify the portfolio and can provide recurring commercial activity outside of investment gains.
Geography
PMGC is headquartered in the United States, but its operating footprint includes U.S.-based subsidiaries and a Canadian research subsidiary. The company’s geography matters because its research activities depend partly on Canadian grants and university relationships, while its operating businesses and investment activities are centered in the U.S. The mix also creates foreign-currency exposure through the Canadian dollar functional currency of PMGC Research Inc.
Risks
PMGC faces execution risk because its value creation depends on acquiring, integrating, and financing a diverse set of businesses and assets. Its biosciences initiatives also carry development, regulatory, and commercialization risk, while the operating subsidiaries face customer concentration, manufacturing, and working-capital pressures typical of small industrial businesses. Foreign-currency translation, valuation judgments, and derivative liabilities add financial reporting complexity.
The business model relies on buying and managing multiple subsidiaries and assets, which can fail to create value if integration or underwriting is weak.
Exposure: PMGC Capital LLC and newly acquired operating businesses
NorthStrive BioSciences depends on successful validation and IND progression before its assets can be commercialized or licensed.
Exposure: EL-22 and other biosciences assets
Precision manufacturing and packaging subsidiaries may face customer concentration, demand swings, and execution constraints.
Exposure: AGA Precision Systems and Pacific Sun Packaging
PMGC Research is Canadian-dollar functional, so translation can affect reported results and equity.
Exposure: Canadian subsidiary operations
Investments, derivative liabilities, and stock-based awards require judgment and can create earnings volatility.
Exposure: Investment portfolio and financing instruments
Accounting
Judgemental itemsDifferent operating units use different timing methods, which affects comparability across periods and segments.
Impact: Pacific Sun Packaging recognizes revenue on shipment/delivery; AGA uses over-time input methods
The holding-company and financing activities can produce mark-to-market gains and losses that do not reflect operating cash flow.
Impact: Can materially affect reported earnings and balance-sheet volatility
Acquired businesses and intangible assets must be tested for recoverability if performance weakens.
Impact: Potential write-downs of assets and goodwill/intangibles
PMGC Research uses the Canadian dollar as functional currency, creating translation effects in consolidation.
Impact: Affects accumulated other comprehensive income and reported results
Similar listed companies
Publicly listed companies with a comparable business focus.
Mustang Bio, Inc
MBIO · Pharmaceutical Preparations
Precigen, Inc
PGEN · Pharmaceutical Preparations
PMV Pharmaceuticals, Inc.
PMVP · Pharmaceutical Preparations
PMV Pharmaceuticals is a U.S.-based clinical-stage biotechnology company focused on developing small-molecule cancer therapies, with an emphasis on genomically defined tumors.
Fulgent Genetics, Inc.
FLGT · Services-Medical Laboratories
PPG Industries, Inc
PPG · Paints, Varnishes, Lacquers, Enamels & Allied Prods
PPG Industries is a U.S.-based manufacturer and distributor of paints, coatings, adhesives, sealants, and specialty materials.
Labcorp Holdings Inc
LH · Services-Medical Laboratories
Last updated: 24/09/2026